$325.00
Sermorelin is a synthetic growth hormone–releasing hormone (GHRH 1-29) analog studied for its role in stimulating endogenous growth hormone secretion within research models. It is evaluated for its influence on pituitary signaling, GH pulsatility, and downstream IGF-1 pathway dynamics.
As a shorter-chain GHRH analog, Sermorelin is examined in laboratory environments for physiologic growth hormone modulation rather than direct hormone replacement mechanisms.
Research Name: Sermorelin
Alias: GHRH (1-29), GRF 1-29
Category: GHRH analog peptide
Primary Research Focus: Growth hormone pulsatility, IGF-1 pathway modeling, metabolic signaling
Format: Lyophilized powder
Upon reconstitution with an appropriate volume of bacteriostatic water, final concentration will vary depending on total diluent added. Researchers calculate concentration using the standard formula:
Total mg in vial ÷ Total mL added = mg per mL
For U-100 insulin syringes:
1 mL = 100 units
Units required are determined by dividing the desired mg amount by the final mg/mL concentration.
Sermorelin is studied for its potential influence on:
Growth Hormone Axis Activity
Endogenous GH pulse stimulation
Pituitary response modeling
IGF-1 trend evaluation
Metabolic Signaling
Lipid metabolism pathways
Body-composition trend observation
Energy utilization frameworks
Recovery & Anabolic Pathways
Protein synthesis signaling
Muscle-repair modeling
Sleep-related GH pulse analysis
Because it stimulates upstream GHRH receptors, Sermorelin supports physiologic GH release patterns rather than supplying exogenous hormone.
Within structured research environments, investigators may observe:
Dose-dependent variables
IGF-1 fluctuations
Transient flushing
Mild water retention
Endocrine-related observations
Changes in appetite patterns
Sleep-cycle shifts in GH studies
Glucose variability
Less frequent observations
Headache
Injection-site irritation
Temporary lightheadedness
Monitoring commonly includes endocrine markers when evaluating GH-axis compounds.
Administration Frequency: Commonly daily within study models
Common Study Duration: 8–12 weeks
Titration Strategy: Incremental adjustments to evaluate hormonal response
Researchers may avoid combining Sermorelin with other GH-releasing compounds unless specifically studying additive pathway effects.
Store lyophilized vial in a cool, dry environment.
Refrigerate after reconstitution.
Maintain sterile laboratory handling procedures at all times.
